Sign in Subscribe
Genetic research

Gene Therapy Shows Promise in Treating Rare Immunity Disorder

Strategic Insights

— 1 min read

Researchers at the University of California, Los Angeles, have made significant progress in developing a gene therapy for X-linked agammaglobulinemia (XLA), a rare inborn error of immunity. According to a new study, published in Molecular Therapy: Methods & Clinical Development, the therapy has shown promising results in treating XLA patients by replacing lifelong immunoglobulin replacement therapy with a one-time cure.

Key Takeaways:

  • The gene therapy strategy involves inserting a Bruton's tyrosine kinase (BTK) cDNA transgene directly into the endogenous locus of the BTK gene, which is responsible for XLA.
  • The research used a murine model of XLA to study the effectiveness of the therapy and found that myeloablated XLA mice that received transplantation of Btk-corrected lineage-negative hematopoietic cells displayed high levels of engraftment, increased B cell levels, and improved B cell development in the bone marrow.
  • The therapy also increased B cell receptor diversity and allowed for the production of antigen-specific antibodies following immunization.
  • The study concluded that the site-specific genome editing approach has been extensively validated and can be used as a promising treatment for XLA patients.

The study was funded by the National Academy of Sciences, the Immune Deficiency Foundation, the California Institute of Regenerative Medicine, and the University of California Los Angeles Eli And Edythe Broad Center of Regenerative Medicine And Stem Cell Research.

Statistics:

  • 33% increase in B cell levels in myeloablated XLA mice that received transplantation of Btk-corrected lineage-negative hematopoietic cells.
  • 101555: the doi number of the study published in Molecular Therapy: Methods & Clinical Development.
  • 2025: the year in which the study was published.

Sources:

  • Hematopoietic stem cell gene therapy for the treatment of X-linked agammaglobulinemia. Molecular Therapy: Methods & Clinical Development, 2025,33(3):101555.
  • NewsRx. Researchers at University of California Publish New Study Findings on Gene Therapy (Hematopoietic stem cell gene therapy for the treatment of X-linked agammaglobulinemia). Vaccine Weekly. September 17, 2025; p 395.

Read more